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Key points: 
1. Single cell approaches identify regulators of malignant HSC self-renewal 
2. Identification of novel roles for Bmi1, Pbx1 and Meis1 in myeloproliferative 
neoplasms 
 
Abstract 
Recent advances in single cell technologies have permitted the investigation 
of heterogeneous cell populations at previously unattainable resolution. Here we 
apply such approaches to resolve the molecular mechanisms driving disease in 
mouse hematopoietic stem cells (HSCs), using JAK2V617F mutant 
myeloproliferative neoplasms (MPNs) as a model. Single cell gene expression and 
functional assays identified a subset of JAK2V617F mutant HSCs that display 
defective self-renewal. This defect is rescued at the single HSC level by crossing 
JAK2V617F mice with mice lacking TET2, the most commonly co-mutated gene in 
MPN patients. Single cell gene expression profiling of JAK2V617F-mutant HSCs 
revealed a loss of specific regulator genes, some of which were restored to normal 
levels in single TET2/JAK2 mutant HSCs. Of these, Bmi1 and, to a lesser extent, 
Pbx1 and Meis1, overexpression in JAK2-mutant HSCs could drive a disease 
phenotype and retain durable stem cell self-renewal in functional assays. Together, 
these single cell approaches refine the molecules involved in clonal expansion of 
MPNs and have broad implications for deconstructing the molecular network of 
normal and malignant stem cells. 
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Introduction  
 Billions of blood cells are produced and destroyed each day1 and 
hematopoietic stem cells (HSCs) must provide sufficient progenitors for 
hematopoiesis while also maintaining their numbers. Malignancy results from 
disturbances in this balance, leading to the production and expansion of HSC clones 
with differentiation and/or proliferation abnormalities2-4. Genetic mutations often 
drive these changes and have been a major focus for cancer researchers5 
The molecular function of individual mutations and their role in disease is 
less clear and the combinatorial action of multiple mutations is nearly completely 
uncharted. In most malignancies, there are numerous recurrent driver mutations, 
resulting in a wide array of mutation combinations, presenting significant 
challenges for discerning disease relevant biology6. The myeloproliferative 
neoplasms (MPNs) are genetically less complicated than the vast majority of 
malignancies7 and are an excellent model for delineating the impact of mutation 
combinations in early tumorigenesis. A single acquired JAK2V617F mutation was 
reported to be present in most MPN patients8-11 and subsequent studies identified 
a number of recurrent mutations found to collaborate with JAK2V617F12-14, 
suggesting that on its own JAK2V617F is insufficient to initiate disease.  
Several groups have developed JAK2V617F knock-in mouse models to study 
the effect of physiological levels of JAK2V617F (reviewed in 15). Although not 
phenotypically identical, these models uniformly develop an MPN phenotype with 
increased myeloid cell production in the erythrocytic and/or megakaryocytic lineage 
with some increases in granulocytic/monocytic lineages15,16. These phenotypes are 
transplantable and can transform to more severe forms of disease (e.g., 
myelofibrosis and/or AML). When HSC self-renewal was tested in serial 
transplantation experiments, HSCs from JAK2V617F knock-in models did not 
outcompete wild-type HSCs, again supporting the notion that JAK2V617F on its 
own was insufficient to initiate disease17-19.  
The most commonly co-mutated gene in JAK2V617F-positive MPNs is TET2 
where loss-of-function mutations are thought to give a clonal advantage to the 
HSCs13,20,21. Recently, both a transgenic and a heterozygous JAK2V617F knock-in 
model were crossed with a Tet2 knock-out and formally demonstrated that loss of 
TET2 could confer a self-renewal advantage on JAK2V617F-mutant HSCs, resulting 
in a robust serially transplantable disease22,23. The molecular basis for this self-
renewal advantage in long-term HSCs (LT-HSCs) remains undetermined and is 
complicated by heterogeneity in the HSC compartment.  
In order to resolve this heterogeneity and to identify which molecules drive 
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the increased self-renewal capacity of a malignant clone, we undertook a single cell 
approach. By profiling homozygous JAK2V617F-mutant HSCs in cell biological and 
molecular assays, we identify key HSC self-renewal regulators that were lower or 
absent in a subset of single-mutant HSCs. Our results highlight the power of single 
cell approaches for identifying molecular profiles and for interrogating essential 
components responsible for each aspect of disease phenotype.    
 
Methods  
Mice 
Homozygous JAK2V617F (JAK HOM) knock-in mice19 were crossed with Tet2 KO 
(TET HOM) mice from Ko et al., 201120.  Full details are available in Supplemental 
Methods.   
 
Isolation of E-SLAM HSCs, in vitro assays, and expression profiling 
E-SLAM cells were isolated as described previously24 and full details of their 
isolation and culture are found in the Supplemental Methods.  Single-cell gene 
expression analysis was performed as described previously28 using the Fluidigm 
BioMark system with full details in the Supplemental Methods.  
 
Bone marrow transplantation assays and analysis 
Primary and secondary transplantation assays were performed as described 
previously19 and full details of HSC frequencies, method of transplantation and 
peripheral blood analysis are in the Supplemental Methods. 
 
Overexpression Assays 
Small pools (1500-3600 cells) of CD45+Lin-CD150+CD48- hematopoietic stem and 
progenitor cells (HSPCs) were isolated and transduced with candidate genes as 
described in the Supplemental Methods. 
 
Patient stem and progenitor cell assays 
Fresh blood samples were collected from MPN patients with JAK2 and TET2 
mutations diagnosed according to British Committee for Standards in Haematology 
(BCSH) guidelines. The study was approved by the Cambridge and Eastern Region 
Ethics Committee, and was carried out in accordance with the principles of the 
Declaration of Helsinki. Details of HSPC isolation, in vitro assays and gene 
expression studies are found in the Supplemental Methods. 
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Results 
JAK2V617F drives increased proliferation and differentiation of HSCs in vitro 
To determine the impact of JAK2V617F expression on single HSCs we isolated 
single CD45+EPCR+CD48-CD150+ (E-SLAM) cells (40-50% HSCs by long-term 
transplantation studies24) from a knock-in mouse model expressing either one (JAK 
HET) or two (JAK HOM) copies of human JAK2V617F. HSCs were cultured in 
conditions that support HSC self-renewal (Figure 1A)35, in which cell division 
kinetics, colony size, and mature cell production were assessed. JAK HET HSCs did 
not show significant differences in early divisional kinetics or cell cycle entry but 
did give rise to significantly larger clones (Supplemental Figure 1A), in agreement 
with previous data in the inducible MX1Cre knock-in model25. However, when 
compared to WT cells, JAK HOM HSCs exited quiescence faster and had shorter cell 
cycle transit time, with an increased proportion of HSCs (~20%) having completed 
the first and second division at 48 hours compared to WT controls (Figure 1B-C) 
(p<0.0001). These data were supported by single cell time-lapse imaging and 
tracking of HSCs isolated from WT and JAK HOM animals (n = 2 mice, data not 
shown). Assessment of clonal progeny of individual HSCs showed that colonies from 
JAK HOM HSCs were on average larger (Supplemental Figure 1A), more 
differentiated (Figure 1D) and contained proportionally fewer progenitor cells (KSL: 
c-Kit+, Sca1+, Lin-) (Figure 1E) than clones grown from HSCs obtained from WT 
littermate controls.  
We next undertook Cobblestone-area-forming cell (CAFC) assays, an in vitro 
surrogate for HSC transplantation where test cells are cultured on a stromal cell 
line for >5 weeks and assessed for the presence of haematopoietic colonies26. HSCs 
with less durable self-renewal tend to form colonies at early time points36. HSCs 
from JAK HOM mice gave rise to an increased number of early-CAFCs and a reduced 
number of mid- and late-CAFCs (Figure 1F), suggesting that JAK HOM HSCs have 
altered stem-cell function, in agreement with transplantation experiments showing 
reduced numbers of HSCs in JAK HOM mice19. Taken together, these data show 
that JAK2V617F provides an advantage for progenitor cells resulting in 
overproduction of differentiated cells, and that this expansion comes at the expense 
of LT-HSC self-renewal. 
 
Single cell expression profiling identifies mutant HSCs with reduced 
expression of self-renewal regulators  
To determine the molecular drivers of HSC functional abnormalities, we first 
performed gene expression arrays on sorted E-SLAM HSCs from WT, JAK HET and 
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JAK HOM mice. While the hyper-proliferation observed in progenitors could be 
potentially explained by modest changes in genes regulating the cell cycle, no clear 
differences emerged on a bulk level that could account for the loss of HSC self-
renewal observed (ArrayExpress accession E-MTAB-6878). Since the data in Figure 
1 identified a fraction of JAK2V617F-homozygous HSCs with aberrant behavior in 
vitro, single cell gene expression profiling was performed to determine whether 
some mutant HSCs had altered expression of self-renewal genes. Single phenotypic 
HSCs from 3 JAK HOM (n=277) and 3 WT (n=465) mice were analyzed for the 
expression of 39 transcription factors and self-renewal regulators by multiplexed 
qPCR (genes listed in Supplemental Table 1). Principal component analysis (Figure 
1G) revealed a subset of cells, in which JAK HOM cells are over-represented, that 
are marked by reduced expression of Meis1, Smarcc2, Bmi1, Pbx1, Sfpi1, Runx1, 
Hoxb4, Myb, Lmo2, as indicated by loadings plot shown in Supplemental Figure 2A. 
Single cell analysis further shows that this subset of cells has reduced expression 
of most, if not all, of these regulators in each cell compared to cells in the larger 
cluster (Supplemental Figure 2B), suggesting that reduced expression of these 
genes might contribute to the loss of competitive reconstitution ability observed in 
JAK2V617F HSCs. 
  
Compound loss of Tet2 does not reverse JAK2V617F-induced HSC hyper-
proliferation  
Loss of Tet2 is the most common collaborating mutation observed in JAK2V617F 
positive MPNs12. Previous studies have shown that loss of Tet2 leads to increased 
re-plating capacity in vitro and increased self-renewal in vivo20,21. When 
heterozygous or transgenic JAK2V617F knock-in mice were crossed with TET2 
knockout mice, an accelerated MPN phenotype was observed and BM 
transplantations showed a strong self-renewal advantage over WT and JAK2V617F 
single-mutant controls22,23. Homozygous JAK2V617F knock-in mice have been 
previously documented to have a more substantial loss of HSC self-renewal19 and 
have not previously been combined with other mutations. To first test whether loss 
of TET2 function could rescue the HSC cycling and hyper-proliferation phenotypes 
observed in Figure 1, we crossed the homozygous JAK2V617F knock-in model19 
with a TET2 knock-out model20 (Figure 2A).  
Loss of TET2 alone did not alter exit from quiescence (Figure 2B), divisional 
kinetics (Figure 2C), colony size (Figure 2D) or the proportion of 
differentiated/progenitor cells (Figure 2E-F) compared to WT controls. However 
when loss of TET2 was combined with JAK2V617F homozygosity, entry into cell 
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cycle was accelerated (Figure 2B), cell cycle transit time was increased (Figure 2C), 
and average clone size was increased (Figure 2D), similar to the phenotypes 
observed in JAK2V617F-homozygous HSCs. Clones derived from double-mutant 
HSCs also had an increased proportion of mature lineage marker positive cells 
(Figure 2E) and a decreased proportion of primitive progenitor (KSL) cells (Figure 
2F). Overall therefore, compound loss of TET2 did not rescue the JAK2V617F-
induced cycling and hyper-proliferation phenotypes observed in single in vitro HSC 
functional assays.  
In order to validate these findings in patient samples, we isolated human 
Lin-CD34+CD38-CD90+CD45RA- cells (human HSCs) from MPN patients. Single 
human HSCs were cultured in stem cell maintenance conditions and divisional 
kinetics tracked for 10 days. Individual clones were plated in a colony forming cell 
(CFC) assay for a further 14 days before being harvested for genotyping (Figure 
3A), allowing retrospective assignment of mutational status. No difference was 
observed between TET2-mutant and non-mutant (WT) cells in the time to 1st or 2nd 
cell division (Figure 3B-C) and both JAK2 single and JAK2/TET2 double mutant cells 
had faster divisional kinetics compared to non-mutant cells, with an increased 
proportion having completed 1st and 2nd divisions at 72 hours (JAK p<0.01; JAK 
TET p<0.001) (Figure 3B-C). However, JAK2 single and double-mutant clone size 
was not significantly affected compared to non-mutant cells (Figure 3D), perhaps 
due to the slower speed of human HSCs that take several days to begin dividing. 
Notably, day 10 clones derived from human HSCs with a TET2 mutation were on 
average smaller than non-mutant and JAK2-mutant cells (Figure 3D).  
Together these data show in both mouse models and patient samples that 
JAK2V671F increases proliferation of primary HSCs in the presence or absence of 
a TET2 mutation, and that TET2 loss on its own does not confer a proliferation 
advantage on HSCs in vitro.  
 
Homozygous JAK2V617F combined with loss of TET2 drives a robust 
transplantable myeloproliferative phenotype in vivo 
Competitive transplantation was undertaken to assess the relative ability of bone 
marrow (BM) cells from each genotype to initiate an MPN phenotype. Despite a red 
cell phenotype in the steady state JAK HOM mouse, an MPN phenotype is not 
observed in transplantation experiments using low cell numbers19, likely due to low 
levels of donor cell repopulation. Loss of Tet2 on its own was also insufficient to 
give an MPN phenotype, although donor cell repopulation was quite high 
throughout the experiment. In combination, low cell numbers of double-mutant BM 
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were sufficient to drive a robust serially transplantable MPN phenotype, where 
hyper-proliferation combined with high donor chimerism to give persistently high 
hematocrit (Figure 4A) and hemoglobin (Figure 4B) levels even at limiting cell 
doses (Supplemental Figure 3) and the phenotype was sustained in secondary 
transplantations (Supplemental Figure 4). No consistent significant differences 
were observed in other blood cell parameters throughout the transplantation 
experiments, although recipient numbers were not sufficient to exclude the 
possibility of mild differences or heterogeneous phenotypes.  
In both the primary (Figure 4C) and secondary (Figure 4D) transplantations, 
recipients of JAK HOM BM have low donor chimerism at 16 weeks post-
transplantation, in line with previous data where low numbers (e.g., 1-5 x 105) of 
BM cells were transplanted19. Recipients of TET HOM BM on the other hand were 
successfully repopulated through both primary and secondary transplantations, 
comparable to WT BM transplantation. Recipients of double mutant (JAK HOM TET 
HOM) BM also show persistent donor cell contribution similar to WT, demonstrating 
that TET2 loss rescues the HSC disadvantage observed in JAK HOM BM. Of note, 
the frequency of phenotypic E-SLAM HSCs in donor cell suspensions was highest in 
TET KO mice  
These transplantation data were further supported by the number of 
phenotypic HSCs present in BM samples in primary and secondary recipients 
(Figure 4E-F). Notably, although primary recipients of JAK HOM BM had a normal 
number of phenotypic HSCs, these cells were clearly unable to repopulate 
secondary recipients (Figure 4F). Finally, we performed a limiting dilution 
transplantation assay to determine the minimal number of double-mutant cells 
required to initiate disease. Chimerism levels were similar to transplantations of 
WT BM cells (Supplemental Figure 3A) and doses of 100,000 and 50,000, but not 
10,000 double-mutant cells were able to sustain a red cell phenotype up to 3 
months (Supplemental Figure 3B). These results estimate the disease-initiating cell 
frequency as ~1 in 33,000 double mutant WBM cells, a number similar to the 
expected LT-HSC frequency in normal BM (1 in 20,000). 
 
Single- and double-mutant HSCs have distinct molecular profiles of self-
renewal regulators 
In order to understand the molecular mechanism of increased self-renewal that 
TET2 loss confers on JAK2 mutant HSCs, single cell gene expression profiling was 
performed on TET2 single mutant (TET HOM, n=73) and double mutant (JAK HOM 
TET HOM, n=99) HSCs and these were compared to WT (n=561) and JAK HOM 
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(n=376) HSCs (Supplemental Figures 5). Hierarchical clustering shows five broad 
molecular clusters of cells (Supplemental Figure 5A). Clusters I and II are 
significantly enriched (p < 0.05 and p < 0.005) for JAK HOM HSCs, Cluster III is 
significantly enriched (p < 0.001) for TET HOM HSCs and Cluster IV is significantly 
enriched for WT (p < 0.05) and double mutant cells (p < 0.05). Interestingly, 
Cluster II does not have any TET-single or double-mutant HSCs, a result re-
enforced by the PCA in individual mice (Supplemental Figure 6).  
Single HSCs of all genotypes were next displayed on a single PCA plot and 
t-SNE analysis to help visualise molecular clusters and identify the genes driving 
the differences (Figure 5A and Supplemental Figure 7A). WT HSCs existed in all 
regions of the molecular landscape, whereas JAK HOM HSCs were over-represented 
in a specific region (top left, Figure 5B) and this region was almost completely 
devoid of cells lacking TET2 expression, suggesting that it is a unique molecular 
region exclusive to a minority of WT HSCs and a larger proportion of JAK HOM 
HSCs. The majority of these cells are also found in Cluster II described above. The 
single-mutant TET HOM HSCs (Figure 5C) are predominantly found in a single area 
of the PCA plot (top right) and the double-mutant HSCs are enriched in a different 
region (bottom right, Figure 5D), although a small fraction of double-mutant cells 
are also found with the single-mutant TET HOM HSCs. The genes negatively 
associated with each of these regions are indicated in the loadings plot (Figure 5E) 
implicating genes such as Bmi1, Runx1, and Pbx1 as being involved in the self-
renewal of HSCs (i.e., associated with TET HOM and double-mutant genotypes) 
rather than proliferation (i.e., associated with JAK HOM HSCs). The individual 
expression patterns of these genes across genotypes is displayed by violin plots in 
Supplemental Figure 7B. We also assessed gene expression levels in CD34+CD38- 
HSC-enriched cell fractions from primary patient samples bearing JAK2V617F 
and/or TET2 mutations for these candidates and did not observe genotype-specific 
increases in these candidates (Supplemental Figure 8). This mirrors our results in 
the mouse where bulk studies could not detect differences and is also complicated 
by the large number of non-HSCs and non-mutated cells in the CD34+CD38- 
fraction.   
The single cell profiling provides molecular evidence of distinct HSC states 
and they parallel the unique functional features of HSCs with different genotypes – 
JAK HOM HSCs can exist in a hyper-proliferative, primed state that exits quiescence 
more rapidly, TET HOM HSCs are in a slow-dividing, durably self-renewing state, 
and the majority of double-mutant HSCs are both highly proliferative and possess 
durable self-renewal (Figure 5F). Since each distinct molecular profile could be 
10 
 
identified in WT HSCs – although sometimes at a low frequency – these data 
suggest that WT HSCs are a heterogeneous mix of cells in distinct proliferative and 
self-renewing states. JAK2 and TET2 mutations disrupt the balance of HSC 
molecular subtypes by restricting the number of HSC states and subsequently, via 
their downstream progeny, lead to an MPN phenotype. 
 
Overexpression of Bmi1, Pbx1, or Meis1 can sustain an MPN phenotype in 
JAK HOM HSCs in vivo 
Since these experiments were performed on single HSCs, the clustering diagram 
and differential enrichment by genotype (Supplemental Figure 5A-B) in 
combination with the loadings plot (Figure 5E) can be used to identify which genes 
might define molecular subtypes and identify candidates for re-balancing the HSC 
pool. For example, double-mutant cells (which have restored self-renewal but still 
proliferate rapidly) cluster away from JAK HOM single-mutant cells (which have 
high proliferation but lack durable self-renewal), allowing us to narrow the list of 
candidate genes that drive the self-renewal advantage (e.g., increased Bmi1, Pbx1, 
Runx1, and Gfi1 and decreased Gfi1b and Dnmt3a). Assessment of individual cells 
in the clustering diagram (Supplemental Figure 5A) confirm these genes are down-
regulated or absent in single JAK HOM HSCs. 
To test which genes might modulate the self-renewal of JAK HOM HSCs, we 
performed lentiviral overexpression and transplantation assays. CD45+Lin-
CD150+CD48- hematopoietic stem and progenitor cells (HSPCs) isolated from either 
JAK HOM or WT mice were transduced with a lentivirus containing a GFP reporter 
and the Bmi1, Pbx1, Runx1 or Meis1 genes. Three days post-infection, cells were 
re-sorted for presence of GFP and transplanted into recipient mice to monitor for 
disease phenotype (Figure 6A).  
The transplantation of limiting doses of JAK2-mutant cells gives a phenotype 
(higher hematocrit and hemoglobin) that fades over time as donor chimerism is 
reduced due to an HSC self-renewal defect19.  As expected, both WT and JAK HOM 
HSPCs infected with an empty vector lentivirus had a comparable engraftment 
(Figure 6B-C, purple line) but the JAK HOM chimerism started to decrease after 16 
weeks post-transplantation and no phenotype was visible at late timepoints (Figure 
6D-E), most likely as a result of donor HSC exhaustion. Runx1 overexpression 
drove both WT and JAK HOM cells to differentiate, with 8 of 10 mice showing no 
almost donor cell contribution at 24 weeks post-transplantation (Figure 6B-C).   
Some mice transplanted with JAK2-mutant cells overexpressing Meis1 (1 of 
5) or Pbx1 (2 of 5) did not sustain donor repopulation out to 24 weeks whereas all 
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mice over-expressing Bmi1 (5 of 5) were successfully repopulated.  Since 3-day 
HSPC-derived cultures represent a mix of HSCs and progenitors, it is possible that 
the Meis1 and Pbx1 failed grafts were due to an inability to drive disease from a 
transduced progenitor cell, whereas Bmi1 may be able to sustain donor 
repopulation from a broader range of cell targets. Overexpression of Meis1, Pbx1 
or Bmi1 in JAK2-mutant HSPCs resulted in hematopoietic phenotypes and in some 
cases, resulted in the premature death of recipient animals (1 Bmi1, 1 Pbx1). Blood 
samples taken prior to death revealed high hematocrit and hemoglobin in both 
cases and post-mortem examination revealed splenomegaly in the mouse receiving 
Bmi1-transduced cells. Repopulated mice from both Meis1-transduced and Bmi1-
transduced JAK2-mutant cells sustained a red cell phenotype as indicated by 
significant increases in hematocrit (0.028 Bmi1; 0.012 Meis1) and hemoglobin 
(0.056 Bmi1; 0.044 Meis1).  Together, these data show that increased Bmi1 
expression, and to a lesser extent Meis1 and Pbx1, can co-operate with JAK2V617F 
to initiate and sustain a myeloproliferative phenotype.  
 
Discussion 
For a leukemia to develop and maintain itself from a single HSC, the HSC and its 
progeny must be able to thrive relative to the endogenous set of non-malignant 
HSCs. The self-renewal and proliferation capacity of each HSC type are therefore 
critical properties to understand. Using single cell gene expression profiling in 
combination with single cell in vitro assays and genetic rescue experiments, this 
study identifies which self-renewal regulators are involved in partnering with 
JAK2V617F to drive a myeloid malignancy. We identify distinct molecular profiles 
that correlate with observed HSC functional properties in mouse models and 
primary patient samples where JAK2V617F drives hyper-proliferation, TET2 loss 
increases self-renewal and double mutant HSCs have increased self-renewal and 
hyper-proliferation. Finally, we test several candidates functionally and reveal a 
novel role for Bmi1 in sustaining the malignant HSC population. 
Several knock-in mouse models have been used to study the impact of 
JAK2V617F on self-renewal of HSCs by undertaking secondary transplantation 
experiments17-19.  Each of these studies showed that heterozygous JAK2V617F on 
its own did not confer a self-renewal advantage to HSCs in competitive secondary 
transplantations. Three possible explanations for the HSC self-renewal defect 
uniquely observed in our JAK HOM model are 1) this is the only model completely 
lacking WT JAK2 in the HSCs tested in competitive serial transplantations; 2) our 
model expresses human, not mouse, JAK2 V617F which might result in different 
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biological consequences; and 3) HSC regulator expression (e.g., Bmi1, Pbx1, 
Meis1, etc) could be different in other knock-in models.  Overall, the lack of 
advantage in competitive serial transplantations suggests that collaborating hits 
are required to give a long-term advantage over non-mutant HSCs. These data 
were further supported by patient-derived xenograft experiments which showed 
that HSCs from patient samples were able to sustain long term engraftment if they 
had both TET2 and JAK2 mutations compared to those with a JAK2 mutation 
alone13. Evidence for genetic collaboration with JAK2V617F in mouse models was 
recently published22, where TET2 knockout mice were crossed with heterozygous 
JAK2V617F knock-in mice37, resulting in a serially transplantable, highly 
competitive myeloproliferative disease, but the molecular and cellular basis for this 
interaction in HSCs remained unclear. On its own, homozygous JAK2V617F 
expression in knock-in mice was shown to induce an MPN phenotype at steady-
state, but disease could not be sustained in a transplantation setting due to a strong 
self-renewal defect19. Our study demonstrates that even this strong HSC self-
renewal defect could be rescued by loss of TET2 and reveals the cellular 
consequences of JAK2 and/or TET2 mutations at single cell resolution.  
Our single cell approach further delineates the key molecular players for 
maintaining malignant HSCs and JAK2V617F-induced disease, while isolating for 
the first time the specific molecular drivers of mutant HSC proliferation and self-
renewal. Approximately 25% of the JAK HOM HSCs lack the key self-renewal 
regulators identified in this study meaning that, as a population, there is a constant 
interplay between these two states.  One potential explanation for the increased 
proportion of cells lacking HSC self-renewal regulators in the JAK2 homozygous 
mouse is that the phenotypic LT-HSC gate (E-SLAM) captures a different proportion 
of HSCs compared to contaminating progenitors than its wildtype littermates (e.g., 
there are more contaminating non-HSCs).  Several lines of evidence suggest this 
would not be the case including the similar reduction in HSC number using an 
alternative sorting gates (Lin-Sca1+Kit+CD34-Flk2-19) and the observation that HSCs 
with similar molecular programmes are present in WT mice (albeit at a lower 
frequency) but not in the TET KO or double-mutant cells (Figure 5).  In either case, 
since our molecular study represents a static picture taken at a single 
developmental stage (3-4 months) and does not give any information regarding 
the dynamics of the HSC compartment, it is not currently possible to resolve the 
relationship of impaired to non-impaired HSCs and we cannot yet ask questions of 
primacy or relatedness.  
Functional studies in vivo showed that Runx1 overexpression resulted in 
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HSC exhaustion in both WT and JAK HOM cells.  In contrast, each of Meis1, Pbx1 
and Bmi1 showed some form of hematopoietic phenotype when over-expressed in 
JAK HOM cells ranging from a lethal hematologic disease to sustained increases in 
hematocrit and hemoglobin.  Bmi1 overexpression in JAK HOM cells was the most 
robust, resulting in a more sustained HSC repopulation and a consistent MPN 
phenotype, aligning with previous studies which demonstrated that Bmi1 
overexpression drives a robust self-renewal increase in primary HSCs38. Notably, 
the phenotype is not as strong as the JAK2/TET2 double-mutant mouse which may 
indicate that a combination of genes is required or that TET2 loss alters the 
epigenetic landscape necessary for MPN development. 
Of note, Bmi1 expression was not changed in the CD34+CD38- HSC enriched 
fraction of MPN patient samples with JAK2 and TET2 mutations and this could be 
due to 1) the vast majority of cells being non-HSCs; and 2) Non-mutant cells with 
normal expression levels masking any changes in Bmi1; and 3) Bmi1 levels only 
changing upon transformation to more severe disease (e.g., AML).  The latter would 
be consistent with the fact that Bmi1 is upregulated in blast crisis CML, MDS, and 
AML and is associated with a worse prognosis39-42, suggesting that increased Bmi1 
expression may play a role in advanced disease stages. 
 Our data suggest that a JAK2V617F mutation would not be sufficient to 
initiate disease on its own; however, a substantial cohort of JAK2V617F-positive 
MPN patients with no known additional driver mutation do exist12. If JAK2V617F 
does not give an intrinsic self-renewal advantage, some additional factor(s) likely 
influence a JAK2-mutant HSC’s outgrowth relative to the other HSCs in the body. 
Several possible explanations exist including: 1) additional genetic or epigenetic 
drivers not yet identified by exome sequencing (e.g., lncRNAs, enhancer elements, 
etc); 2) inherited genetic risk factors where some patients are more susceptible to 
cells gaining a clonal advantage due to defective non-mutant HSCs; and 3) micro-
environmental factors (the physical niche itself or secreted cytokines) that 
encourage the outgrowth of mutant subclones43,44. It is also interesting to note that 
JAK2V617F mutations are found in a substantial percentage of older individuals 
with no obvious blood phenotype45-47. This latter finding is consistent with a low 
number of JAK2V617F HSCs without a significant clonal advantage giving rise to 
more mature cells on a per-HSC basis, but an insufficient number to create an 
observable phenotype in an individual.  
 Single cell technologies at the cell biological and molecular level have now 
reached a level where more sophisticated questions about the molecules operating 
individually or collaboratively can be asked in mouse models of disease and, to a 
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lesser extent, in patient samples. Combinatorial studies of HSCs from mouse 
models with distinct and easily assayable properties permit dissection of molecular 
programs of each biological phenotype. These studies set the stage for targeting 
molecules that might guide HSC fate choice at the population level to restore 
balance throughout the hematopoietic system. 
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Figure Legends  
Figure 1: JAK2V617F induces increased proliferation and differentiation in 
single HSC-derived clones. 
(A) Schematic of single cell in vitro cultures. Single CD45+EPCR+CD48-CD150+ (E-
SLAM) cells were sorted into individual wells and cultured for 10-14 days in 
STEMSPAN with 10% FCS, 300ng/ml SCF and 20ng/ml IL-11 and assessed for 
proliferation, cell cycle kinetics and differentiation. (B, C) Daily cell counts revealed 
that JAK2V617F homozygous HSCs (red line) display faster cell cycle kinetics as 
indicated by a shorter time to first and second division, p<0.0001 at 48 hours 
(three independent experiments). (D, E) Homozygous JAK2V617F HSCs (red bars) 
give rise to an increased number of differentiated cells (positive for Gr1+/Mac1+; 
Lin+) (p=<0.0001) and a reduced number of stem/progenitor cells (Gr1-, Mac1-, c-
Kit+, Sca1+, LSK) (p<0.0001). WT n=100, JAK HET n=189, JAK HOM n=154 (three 
independent experiments). (F) Compared to WT HSCs, JAK HOM HSCs have 
increased early forming cobblestone area forming cells (CAFCs) (p= 0.0086). WT 
n=61, JAK HOM n=62 (two independent experiments). Asterisks indicate significant 
differences by Student t test for D+E, and by chi-squared for B, C and F (*p< 0.05; 
**p< 0.01, *** p <0.001). Data are shown as mean ± SEM. (G) Principal 
component (PC) analysis of all HSCs calculated from the 39 genes analyzed. PC1 
and PC2 account   JAK2V617F HSCs are indicated by red circles and WT HSCs are 
indicated by blue diamonds. A cluster of cells on the right hand side of the graph 
is enriched for JAK2V617F HOM HSCs and have reduced expression of several 
important hematopoietic genes (Meis1, Smarcc2, Bmi1, Pbx1, Sfpi1, Runx1, 
Hoxb4, Myb, Lmo2). Axes are in arbitrary units. WT n=465 JAK HOM n=277. 
 
Figure 2: Loss of Tet2 does not reverse JAK2V617-induced hyper-
proliferation in single HSCs. 
(A) Table summarising the mutations in each genotype and the colour code for the 
remainder of the figures. (B, C) The cumulative times to first (B) and second (C) 
division are shown and were determined by manual daily cell counts, scoring the 
presence of 1, 2, or 3-4 cells. Loss of Tet2 on its own (green line) does not affect 
cell cycling compared to WT (blue line), whereas JAK2V617F on its own (red line) 
increases proliferation (p<0.0001). Compound mutants (JAK HOM TET HOM, 
orange line) behave like JAK2V617F single mutant HSCs with a faster time to first 
and second division respectively (p<0.0001). Data are shown as mean ± SEM. WT 
n=572, JAK HOM n=439, TET HOM n=566, JAK HOM TET HOM n=435 and are from 
3-6 independent experiments (D) Colony size after 9 days in culture. JAK2V617F 
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and double mutant HSCs give rise to a higher frequency (p<0.0001 and <0.0001) 
of large colonies compared to WT controls. Colonies were categorised as very small 
(>50), small (51-500), medium (501-10,000) or large (>10,000). WT n=572, JAK 
HOM n=439, TET HOM n=566, JAK HOM TET HOM n=435. (E, F) After 10 days in 
culture, colonies were analyzed by flow cytometry for differentiation markers. 
Colonies with JAK2V617F (JAK HOM (red bars) and JAK HOM TET HOM (orange 
bars)) have an increased frequency of Lin+ cells (Ly6g+, Mac1+)(JAK HOM 
p<0.0001, JAK HOM TET HOM p=0.0177). Double mutants (orange bars) and JAK 
HOM (red bars) show a reduced frequency of KSL (Ly6g-, Mac1-, c-Kit+, Sca1+) cells 
compared to WT (blue bars) and TET HOM (green bars) (JAK HOM TET HOM 
p=0.001, JAK HOM p<0.0001). WT n=165, JAK HOM n=178, TET HOM n=154, JAK 
HOM TET HOM n=145 (three independent experiments). 
 
Figure 3: JAK2 V617F-mutant patient HSCs proliferate faster than TET2-
single mutant and non-mutant cells.   
(A) Schematic of experimental design. Single Lin-CD34+CD38-CD90+CD45RA- cells 
were sorted from MPN patient peripheral blood samples (n=12, 3 ET, 5 PV. 4 sMF) 
into 96 well plates and cell counts were performed daily for 10 days. On day 9-10, 
clones were harvested and plated in a colony forming cell assay and the colonies 
produced were harvested for genotyping. Several patient assays were originally 
performed for a previous study34 and were pooled together with newly generated 
data. (B, C) Human HSCs with a TET mutation alone (n=2 patients, green line) 
have similar divisional kinetics to non-mutant HSCs (blue line), whereas cells with 
a JAK2 V617F mutation alone (n=10 patients, red line) or both mutations (orange 
lines) had a reduced time to first (B) and second (C) divisions (higher proportion 
completed division at 72hrs, JAK p <0.01, JAK TET p<0.001). WT n=114, JAK 
n=108, TET n=40, JAK TET n=183. Patients with genotyped colonies: WT N=11, 
TET alone N=2, JAK alone N=11, JAK TET together N=8. (D) Compared to WT cells, 
cells with TET mutations gave rise to a higher proportion of very small clones (<50 
cells) (p<0.0001). WT n=114, JAK n=108, TET n=40, JAK TET n=183. 
 
Figure 4: Double JAK/TET mutant cells have a clonal advantage and result 
in a sustained myeloproliferative phenotype in transplantation. 
Bone marrow transplantations were performed and peripheral blood was analyzed 
for donor cell chimerism and blood parameters. Only recipients of double mutant 
bone marrow have persistently high haematocrit (A) (p<0.01 at 16 weeks) and 
haemoglobin (B) (p<0.01 at 16 weeks). Donor cell chimerism at 16 weeks in 
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primary (C) and secondary (D) transplantations is displayed. Whereas JAK2V617F 
cells (red bars) are less competitive relative to WT cells (blue bars) (p<0.01), those 
with a single TET mutation (green bars) or double mutants (JAK HOM TET HOM, 
orange bars) were similar to WT cells, indicating no deficiency in self-renewal. (E, 
F) Mean proportion of E-SLAM HSCs in donor cells in bone marrow, 24 weeks post 
transplantation, from primary (E) and secondary (F) recipients. In double mutant 
recipients, E-SLAM numbers were not different compared to WT, whereas JAK2 
single mutant recipients have lost both phenotypic and functional HSCs.  
 
Figure 5: Single cell gene expression profiling reveals distinct molecular 
clusters of single and double mutant HSCs with altered self-renewal and 
proliferation.  
Cells from all four genotypes were assessed by single cell multiplexed qPCR and 
each PCA plot displays all single cells analyzed (with one population highlighted in 
each plot) (A-D) Principal component analysis displays on a single plot, HSCs from 
WT (n=561, blue circles), JAK HOM (n=376, red circles), TET HOM (n=73, green 
circles), JAK HOM TET HOM (n=99, orange circles). Notably, WT cells are present 
across the entire molecular landscape whereas single- and double-mutant HSCs 
are enriched in specific regions. (E) Loadings plot for PCA indicating the key defining 
molecular features of each region with the distance from the centre indicating the 
negative correlation with a cell type (e.g., cells in the top right lack Vwf). (F) 
Illustration depicting the different cell characteristics associated with each region 
of the molecular landscape.  
 
Figure 6: Overexpression of Bmi1, Meis1, and Pbx1 in JAK2-mutant HSCs 
enhance MPN-like phenotype in vivo. (A) Schematic of candidate gene 
overexpression transplants. Bulk CD45+Lin-CD48-CD150+ (HSPC) cells (300-800 
per mouse) were sorted from WT and JAK HOM mice and infected with lentivirus 
carrying no gene (empty vector) or lentivirus carrying genes to overexpress Bmi1, 
Pbx1, Runx1, or Meis1 (two independent experiments). Three days after infection 
GFP+ cells (300-2000) were isolated and transplanted into recipient mice. Serial 
analysis of peripheral blood was performed to assess chimerism (B and C, n=4-5 
recipients) and blood cell parameters (D and E). Hematocrit (Hct) and hemoglobin 
(Hgb) at 20 weeks post-transplantation for JAK HOM cells over-expressing each 
gene, compared to WT cells transduced with the same construct (D and E). 
Successfully repopulated JAK HOM cells over-expressing either of Meis1 or Bmi1 
display a strong erythrocytic phenotype compared to JAK HOM cells transduced 
19 
 
with the empty vector with * indicating p<0.05 and a dark circle indicating a mouse 
which died prior to the 20-week timepoint (unrelated to transplantation in the mice 
receiving Runx1-transduced and the non-phenotypic Pbx1-transduced cells). 
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